UY35205A - Dihidropiridopirazinonas inhibidoras de la proteína bet - Google Patents
Dihidropiridopirazinonas inhibidoras de la proteína betInfo
- Publication number
- UY35205A UY35205A UY0001035205A UY35205A UY35205A UY 35205 A UY35205 A UY 35205A UY 0001035205 A UY0001035205 A UY 0001035205A UY 35205 A UY35205 A UY 35205A UY 35205 A UY35205 A UY 35205A
- Authority
- UY
- Uruguay
- Prior art keywords
- inhibitors
- bet protein
- disorders
- dihydropiridopirazinonas
- compounds according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a dihidropiridopirazinonas inhibidoras de la proteína BET, especialmente inhibidoras de BRD4, de fórmula general (I) en la que A, X, R1, R2, R3, R4, R4, R6, R7 y n tienen los significados dados en la descripción, a intermedios para la preparación de los compuestos de acuerdo con la invención, a composiciones farmacéuticas que comprenden los compuestos de acuerdo con la invención y al uso profiláctico y terapéutic o de los mismos en el caso de trastornos hiperproliferativos, especialmente en el caso de trastornos neoplásicos. Esta invención también se refiere al uso de inhibidores de la proteína BET en infecciones virales, en trastornos neurodegenerativos, en enfermedades inflamatorias, en trastornos ateroscleróticos y en el control de la fertilidad masculina
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12198623 | 2012-12-20 | ||
EP13182252 | 2013-08-29 | ||
EP13191933 | 2013-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35205A true UY35205A (es) | 2014-07-31 |
Family
ID=49779903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035205A UY35205A (es) | 2012-12-20 | 2013-12-19 | Dihidropiridopirazinonas inhibidoras de la proteína bet |
Country Status (10)
Country | Link |
---|---|
US (1) | US20160193206A1 (es) |
EP (1) | EP2935260A1 (es) |
JP (1) | JP2016504990A (es) |
CN (1) | CN105229002A (es) |
AR (1) | AR094148A1 (es) |
CA (1) | CA2895404A1 (es) |
HK (1) | HK1213899A1 (es) |
TW (1) | TW201427981A (es) |
UY (1) | UY35205A (es) |
WO (1) | WO2014095774A1 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160193206A1 (en) * | 2012-12-20 | 2016-07-07 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydropyridopyrazinones |
US9227985B2 (en) | 2013-03-15 | 2016-01-05 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
CA2917562A1 (en) * | 2013-07-09 | 2015-01-15 | Bayer Pharma Aktiengesellschaft | Modified bet-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones |
WO2015013635A2 (en) | 2013-07-25 | 2015-01-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
EP3099171A4 (en) * | 2014-01-31 | 2017-08-09 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
RU2016134947A (ru) | 2014-01-31 | 2018-03-01 | Дана-Фарбер Кансер Институт, Инк. | Производные диаминопиримидин бензолсульфона и их применение |
JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジアゼパン誘導体の使用 |
HUE061770T2 (hu) | 2014-04-23 | 2023-08-28 | Incyte Holdings Corp | 1H-pirrolo[2,3-C]piridin-7(6H)-onok és pirazolo[3,4-C]piridin-7(6H)-onok mint BET fehérjék gátlószerei |
CN106573931A (zh) * | 2014-06-18 | 2017-04-19 | 拜耳医药股份有限公司 | 抑制BET蛋白的具有间位取代的芳族氨基或醚基的3,4‑二氢吡啶并[2,3‑b]吡嗪酮 |
WO2015193217A1 (de) * | 2014-06-18 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische dihydropyrido[2,3-b]pyrazinon-derivate mit para-substituierter aromatischer amino- oder ethergruppe |
KR102633122B1 (ko) | 2014-08-01 | 2024-02-05 | 누에볼루션 에이/에스 | 브로모도메인에 대하여 활성을 갖는 화합물 |
JP2017525759A (ja) * | 2014-08-08 | 2017-09-07 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | ジヒドロプテリジノン誘導体およびその使用 |
RU2017104897A (ru) | 2014-08-08 | 2018-09-10 | Дана-Фарбер Кэнсер Инститьют, Инк. | Производные диазепана и их применения |
US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
JP6930913B2 (ja) | 2014-10-14 | 2021-09-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California | 炎症を阻害するためのcdk9及びbrd4阻害剤の使用法 |
GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
US10501438B2 (en) | 2015-08-11 | 2019-12-10 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
WO2017024406A1 (en) * | 2015-08-11 | 2017-02-16 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
EP3334719B1 (en) | 2015-08-12 | 2021-09-15 | Neomed Institute | Substituted benzimidazoles, their preparation and their use as pharmaceuticals |
US11306105B2 (en) | 2015-09-11 | 2022-04-19 | Dana-Farber Cancer Institute, Inc. | Cyano thienotriazolodiazepines and uses thereof |
SG10202007099TA (en) | 2015-09-11 | 2020-08-28 | Dana Farber Cancer Inst Inc | Acetamide thienotriazoldiazepines and uses thereof |
WO2017066876A1 (en) | 2015-10-21 | 2017-04-27 | Neomed Institute | Substituted imidazopyridines, their preparation and their use as pharmaceuticals |
AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
CN114957291A (zh) | 2015-11-25 | 2022-08-30 | 达纳-法伯癌症研究所股份有限公司 | 二价溴结构域抑制剂及其用途 |
US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
DE102017005091A1 (de) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituierte 3,4-Dihydropyrido[2,3-b]pyrazin-2(1H)-one |
EP3472157B1 (en) | 2016-06-20 | 2023-04-12 | Incyte Corporation | Crystalline solid forms of a bet inhibitor |
CN109350616B (zh) * | 2018-12-18 | 2020-04-21 | 南华大学 | I-brd9或其衍生物在制备抗癫痫药物中的应用 |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
CN113717080A (zh) * | 2021-10-09 | 2021-11-30 | 西安瑞联新材料股份有限公司 | 一种4-氯-2-氰基苯磺酰氯的合成方法 |
WO2023205251A1 (en) | 2022-04-19 | 2023-10-26 | Nuevolution A/S | Compounds active towards bromodomains |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19506742A1 (de) * | 1995-02-27 | 1996-08-29 | Bayer Ag | Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen |
US7351709B2 (en) * | 2004-06-09 | 2008-04-01 | Wyeth | Estrogen receptor ligands |
EP2078016B1 (en) * | 2006-10-19 | 2012-02-01 | Signal Pharmaceuticals LLC | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
JP2012197231A (ja) * | 2009-08-06 | 2012-10-18 | Oncotherapy Science Ltd | Ttk阻害作用を有するピリジンおよびピリミジン誘導体 |
CA2799373A1 (en) * | 2010-05-14 | 2011-11-17 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating metabolism |
US20160193206A1 (en) * | 2012-12-20 | 2016-07-07 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydropyridopyrazinones |
-
2013
- 2013-12-17 US US14/654,572 patent/US20160193206A1/en not_active Abandoned
- 2013-12-17 CN CN201380073359.5A patent/CN105229002A/zh active Pending
- 2013-12-17 EP EP13807998.3A patent/EP2935260A1/de not_active Withdrawn
- 2013-12-17 CA CA2895404A patent/CA2895404A1/en not_active Abandoned
- 2013-12-17 JP JP2015548421A patent/JP2016504990A/ja not_active Ceased
- 2013-12-17 WO PCT/EP2013/076784 patent/WO2014095774A1/de active Application Filing
- 2013-12-19 AR ARP130104872A patent/AR094148A1/es unknown
- 2013-12-19 TW TW102147272A patent/TW201427981A/zh unknown
- 2013-12-19 UY UY0001035205A patent/UY35205A/es not_active Application Discontinuation
-
2016
- 2016-02-19 HK HK16101861.6A patent/HK1213899A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
US20160193206A1 (en) | 2016-07-07 |
EP2935260A1 (de) | 2015-10-28 |
WO2014095774A1 (de) | 2014-06-26 |
TW201427981A (zh) | 2014-07-16 |
AR094148A1 (es) | 2015-07-15 |
HK1213899A1 (zh) | 2016-07-15 |
JP2016504990A (ja) | 2016-02-18 |
CN105229002A (zh) | 2016-01-06 |
CA2895404A1 (en) | 2014-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35205A (es) | Dihidropiridopirazinonas inhibidoras de la proteína bet | |
PE20150729A1 (es) | 2,3-benzodiazepines | |
CL2012001821A1 (es) | Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
DOP2015000274A (es) | Compuestos químicos | |
CL2015002301A1 (es) | Acido 2-aza-biciclo[2.2.1]heptano-3-carboxílico (bencil-ciano-metil)-amidas sustituidas inhibidores de catepsina c. | |
CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
PE20151501A1 (es) | Inhibidores de prmt5 y sus usos | |
EA201500926A1 (ru) | Фумараты как пролекарства и их применение при лечении различных заболеваний | |
ECSP12012318A (es) | Inhibidores de pirazolil quinazolina cinasa | |
BR112015011456A2 (pt) | compostos de aminopirimidina como inibidores de egfr mutantes contendo t790m | |
CR20160033A (es) | Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromático-bencil-amida | |
BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
BR112015032693A2 (pt) | inibidores de bromodomínio | |
BR112015020118A2 (pt) | derivados de 2-aminopirimidina para o tratamento de infecções virais | |
DOP2014000115A (es) | Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
BR112013019011A2 (pt) | inibição de il17 e ifn-gama para o tratamento de inflamação autoimune | |
BR112015000399A2 (pt) | derivados de pirazolil pirimidina | |
PE20151979A1 (es) | Compuestos quimicos | |
BR112015007366A2 (pt) | derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças | |
CL2015000408A1 (es) | Compuestos derivados de pirazolo[4,3-d]pirimidina y sus sales; composicion farmaceutica que los comprende, util para el tratamiento de enfermedades alergicas, inflamatorias, infecciosas o cancer. | |
CO2018002211A2 (es) | Piridinona dicarboxamida para su uso como inhibidores de bromodominio | |
UY35654A (es) | Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet | |
CR20150426A (es) | 2,3-benzodiazepinas biciclo y espirocíclico sustituidas | |
UA110048C2 (uk) | Інгібування il17 і ifn-гамма для лікування аутоімунного запалення |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20210715 |